Over 10,000 peer-reviewed scientific publications, and the 2009 Nobel Prize in Physiology or Medicine, relate to telomere biology and aging or disease. Many of these articles support the diagnostic utility of telomere-related measurements to monitor health status, disease risk, prognosis, and drug response. Some of these studies establish both associations and causal links between short telomeres or altered telomerase levels and major diseases including cancer, cardiovascular, fibrotic, inflammatory and infectious diseases, depression, and diabetes. While most biomarkers are specific for certain diseases, telomere shortness is a parameter uniquely predictive of an increased risk of many diseases. In some studies, it is superior to conventional biomarkers.
The multiple applications of telomere-based diagnostics measurement toward prevention, wellness, and individualized treatment can support a paradigm shift for healthcare.
About Telomere Diagnostics, Inc. (TDx, previously known as Telome Health, Inc.)
TDx was founded by four of the most renowned world experts in Telomere Biology, with 80 cumulative years of research in the field, more than tens of thousands of citations and a Nobel Laureate in Physiology or Medicine. TDx founders believe that telomere length as an overall index of health will be an integral component in the personalized medicine revolution, which includes individualized health maintenance plans based on new health monitoring tools.
TDx leverages the predictive power of data related to telomeres, the protective caps at the ends of chromosomes, and telomerase, the enzyme that increases the length of the telomeres, to help assess health status, disease and mortality risk, and response to specific therapies. As the field of telomere biology continues to evolve, TDx will develop and commercialize additional diagnostics based on telomere biology. The company cur
|SOURCE Telomere Diagnostics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved